Associated tags: CRISPR Therapeutics, Patient, Therapy, Pharmaceutical industry, Associate, Hypoglycemia, Regenerative medicine, SAN, Potency (pharmacology), Cell encapsulation, W. L. Gore & Associates, Protein, Diabetes, University
Retrieved on:
Wednesday, January 19, 2022
Duke University School of Medicine,
Patient,
Accounting,
Brigham,
Associate,
Hypoglycemia,
LinkedIn,
Amylin Pharmaceuticals,
SAN,
Hypertension,
Board of directors,
Cell encapsulation,
CRISPR Therapeutics,
Protein,
LLP,
W. L. Gore & Associates,
Leadership,
Virtual College of Biotechnology, University of Saskatchewan,
Regenerative medicine,
History of the College of William & Mary,
View,
Duke University Hospital,
Industry,
Therapy,
Brigham and Women's Hospital,
Diabetes,
Company,
Drug development,
GlaxoSmithKline Pharmaceuticals Ltd,
Hospital,
University,
Multimedia,
Type 2 diabetes,
Potency (pharmacology),
Risk,
PricewaterhouseCoopers,
Twitter,
College,
Senior,
Board,
Pharmaceutical industry,
Management,
Exenatide,
Facebook,
Operation,
Endocrinology "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
Key Points:
- "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
- "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
- Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases.
- Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics).
Retrieved on:
Tuesday, November 30, 2021
Patient,
National Executive Committee of the Labour Party,
Semper Fidelis (march),
Legal Affairs,
Government,
Associate,
Hypoglycemia,
Protein,
Executive Committee,
DLA Piper,
BA,
Company,
DLA,
University,
Petco,
W. L. Gore & Associates,
General counsel,
IPO,
Tennessee Student Assistance Corporation,
SAN,
Leadership,
Potency (pharmacology),
Twitter,
View,
Risk,
Cell encapsulation,
Piper,
Regenerative medicine,
CRISPR Therapeutics,
Therapy,
LinkedIn,
Partner,
Pharmaceutical industry,
Management SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Marty Lorenzo as General Counsel.
Key Points:
- SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Marty Lorenzo as General Counsel.
- Mr. Lorenzo brings over 20 years in the legal profession leading corporate transactions and compliance functions.
- "We are excited to have Marty join the ViaCyte management team," said Michael Yang, President and Chief Executive Officer of ViaCyte.
- "I am thrilled to be part of ViaCyte as the Company advances transformational cell therapies to the clinic with the potential to deliver functional cures," said Mr. Lorenzo.
Retrieved on:
Wednesday, October 20, 2021
Associate,
Risk,
View,
Twitter,
CRISPR Therapeutics,
News,
LinkedIn,
Diabetes,
Potency (pharmacology),
SAN,
Regenerative medicine,
Program,
CEO,
Therapy,
Cell encapsulation,
W. L. Gore & Associates,
Hypoglycemia,
Patient,
Protein,
Company,
Pharmaceutical industry,
Online shopping SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that Michael Yang, President & CEO, will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m.
Key Points:
- SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that Michael Yang, President & CEO, will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m.
- A live webcast of this presentation will be available on the Company's News & Events page accessible here: https://viacyte.com/news-events/ .
- To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.
- For more information, please visit www.viacyte.com and connect with ViaCyte on Twitter , Facebook , and LinkedIn .
Retrieved on:
Thursday, October 7, 2021
Company,
Twitter,
Risk,
Therapy,
CRISPR Therapeutics,
SAN,
Associate,
Protein,
W. L. Gore & Associates,
Multimedia,
Mesa,
Diabetes,
LinkedIn,
Industry,
View,
Hypoglycemia,
Cell encapsulation,
Cell,
Insulin,
CA,
Potency (pharmacology),
Patient,
Regenerative medicine,
Medical device,
Pharmaceutical industry SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021, at 10:15 a.m. PT in Carlsbad, CA.
Key Points:
- SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021, at 10:15 a.m. PT in Carlsbad, CA.
- "Cell replacement therapy has the potential to address the limitations of current therapies and advance the treatment of diabetes," said Mr. Yang.
- ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.
- To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.
Retrieved on:
Monday, September 13, 2021
Laboratory,
Molecular Endocrinology,
Massachusetts,
Therapy,
SAN,
Donald D. Engen,
University,
Center,
CRISPR Therapeutics,
Potency (pharmacology),
Diabetes,
Kyoto University,
Protein,
Patient,
Associate,
Company,
Risk,
Hypoglycemia,
View,
Harvard Medical School,
Canadian Academy of Health Sciences,
LinkedIn,
W. L. Gore & Associates,
Industry,
Hospital,
Cell encapsulation,
Multimedia,
Twitter,
Regenerative medicine,
Outline of health sciences,
Massachusetts General Hospital,
Research,
Pharmaceutical industry SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, today announced the appointment of Timothy Kieffer, Ph.D., as Chief Scientific Officer.
Key Points:
- SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, today announced the appointment of Timothy Kieffer, Ph.D., as Chief Scientific Officer.
- "Tim is a global thought leader and one of the foremost experts in developing stem cell-based therapies for treatment of diabetes," said Michael Yang, Chief Executive Officer, ViaCyte.
- "I am excited to join ViaCyte at this important moment, building on the impressive progress the team has made toward finding a functional cure for diabetes," said Dr. Kieffer.
- ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.
SAN DIEGO, July 21, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.
Key Points:
- SAN DIEGO, July 21, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.
- Dr. Wilensky will be responsible for training surgeons and advancing innovative approaches for ViaCyte's pancreatic islet cell replacement therapies.
- Dr. Wilensky is a board-certified plastic surgeon and joins ViaCyte after having functioned in an advisory capacity to the company since 2014.
- In prior roles, Dr. Wilensky has consulted for numerous other early- and mid-stage companies developing related technologies.
"These results offer clinical proof-of-concept that our islet cell replacement therapy is a promising approach to effectively control blood glucose and, with optimization, has potential to fundamentally change the management of T1D."
Key Points:
- "These results offer clinical proof-of-concept that our islet cell replacement therapy is a promising approach to effectively control blood glucose and, with optimization, has potential to fundamentally change the management of T1D."
- The Company anticipates reporting additional patient data readouts from the PEC-Direct study in the first half of 2022.
- ViaCyte's PEC-Direct (VC-02) product candidate is being developed for treatment of patients with type 1 diabetes who have hypoglycemia unawareness and/or extreme glycemic lability.
- iKeymeulen B, Jacobs-Tulleneers-Thevissen D, Kroon E, Jaiman M, Daniels M, Wang R, Pipeleers D, D'Amour, K, Foyt H.(2021) Stem Cell-Derived Islet Replacement Therapy (VC-02) Demonstrates Production of C-Peptide in Patients with Type 1 Diabetes (T1D) and Hypoglycemia Unawareness.
SAN DIEGO, June 16, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced today that Michael Yang, President & CEO, and Brittany Bradrick, CFO & COO, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021 at 2:00 p.m.
Key Points:
- SAN DIEGO, June 16, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced today that Michael Yang, President & CEO, and Brittany Bradrick, CFO & COO, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021 at 2:00 p.m.
- A live webcast of this presentation will be available on the Company's News & Events page accessible here: https://viacyte.com/news-events/ .
- To accelerate and expand the company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.
- For more information, please visit www.viacyte.com and connect with ViaCyte on Twitter , Facebook , and LinkedIn.
SAN DIEGO, June 8, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced today the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.
Key Points:
- SAN DIEGO, June 8, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced today the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.
- Dr. D'Amour will resign effective June 25, 2021, to pursue other opportunities.The Company has already initiated a search for a successor.
- "We sincerely thank Kevin for playing an integral role in helping the team achieve our scientific goals and wish him the very best in his new endeavors."
- To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.
Branches of biology,
Biology,
Life sciences,
Biotechnology,
Cell biology,
Animal products,
Pancreatic hormones,
Peptide hormones,
Cell encapsulation,
Type 1 diabetes,
Glucagon,
Cell therapy ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.
Key Points:
- ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.
- ViaCyte is currently evaluating open and closed devices to deliver cell replacement therapies for type 1 diabetes (T1D) in Phase 2 clinical trials.
- These devices contain the cell therapy while enabling oxygen and nutrients to flow into the device and insulin, glucagon, and other hormones to flow out.
- www.gore.com
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.
